CXorf48 Is a Potential Therapeutic Target for Achieving Treatment-Free Remission in CML Patients
Blood Cancer Journal - United States
doi 10.1038/bcj.2017.84
Full Text
Open PDFAbstract
Available in full text
Date
September 1, 2017
Authors
Publisher
Springer Science and Business Media LLC